| Iupac Name: | 3-((3R)-3--1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid |
| Tradename: | Baynas |
| Routes Of Administration: | Oral (tablets) |
| Legal Status: | Rx-only (JP) |
| Cas Number: | 116649-85-5 |
| Atc Prefix: | None |
| Pubchem: | 123879 |
| Unii: | P1ALI72U6C |
| Iuphar Ligand: | 1910 |
| Chembl: | 361812 |
| Chemspiderid: | 110413 |
| Kegg: | D01128 |
| C: | 21 |
| H: | 21 |
| F: | 1 |
| N: | 2 |
| O: | 4 |
| S: | 1 |
| Smiles: | C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O |
| Stdinchi: | 1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 |
| Stdinchikey: | LDXDSHIEDAPSSA-OAHLLOKOSA-N |
Ramatroban (INN) (also known as BAY u3405)[1] is a thromboxane receptor antagonist.[2]
It is also a DP2 receptor antagonist.[3]
It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]
It has been suggested that ramatroban, by modulating DP2 receptor, can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced by SARS-Cov-2. Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of COVID-19 disease, although no clinical trial has yet been conducted.[6]
Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.